Virus-specific T cells
Off-the-shelf T cells from healthy donors that recognise Epstein-Barr virus, used to treat virus-driven lymphomas after transplant; tabelecleucel was approved in Europe in 2022.
Overview
Some cancers are driven by viruses whose proteins make excellent T-cell targets. Banks of donor T cells selected for Epstein-Barr virus specificity and matched on HLA can be given off the shelf; tabelecleucel (Ebvallo) was approved in the European Union in 2022 for EBV-positive post-transplant lymphoproliferative disease that has failed other treatment. Similar products target cytomegalovirus and adenovirus after transplant, and EBV-directed cells are tested in nasopharyngeal carcinoma.
How it works
Donor T cells are expanded against viral antigens, banked by HLA type, and selected for each patient to share at least one restricting allele, then infused without lymphodepletion.
- Off the shelf with rapid access
- Very low toxicity
- Approved in Europe
- Only virus-associated cancers
- HLA matching still required
- Not approved in the United States
Latest papers
topQuery for this technology: (TITLE:"Virus-specific T cells" OR ABSTRACT:"Virus-specific T cells") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Virus-specific T cells, not a curated reading list.
Similar pages
not linked directly; found by shared links- TechnologyNK cell therapy and CAR-NK
Shares Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.
- CompanyIndapta Therapeutics
Shares Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.
- CompanyImugene
Shares Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.
- IdeaNon-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route
Shares Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.
- PersonStephen J. Forman
Shares Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.
- CompanyPoseida Therapeutics
Shares Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.
- CompanyCaribou Biosciences
Shares Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.
- PersonKatayoun Rezvani
Shares Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.